MeSH D061218 - treatment-resistant depressive disorder
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Johnson & Johnson | Esketamine | Spravato | 2027-03-20 | 2019-03-05 | $708 M | Q1/23-Q1/24 |
Clinical Trials
Historical Success Rate
Phase 1
64%9/14
Phase 2
35%9/26
Phase 3
56%14/25
Approved: 1Overall Success rate: 12%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use